交易 CSPC Pharmaceutical Group Limited - 1093 CFD
加入收藏夹- 概括
- 曆史數據
- 活動
- 收入報表
- 資産負債表
- 現金流
- 所有權
交易條件
| 价差 | 0.30 | ||||||||
|
多头隔夜费
多头隔夜费
前往平台 | -0.026116% | ||||||||
|
空头隔夜费
空头隔夜费
前往平台 | 0.004199% | ||||||||
| 隔夜费时间 | 22:00 (UTC) | ||||||||
| 最小交易量 | 1 | ||||||||
| 货币 | HKD | ||||||||
| 保证金 | 5% | ||||||||
| 上市交易所 | Hong Kong | ||||||||
| 交易费 | 0% |
*Information provided by Capital.com
CSPC Pharmaceutical Group Ltd ESG Risk Ratings
High Medium Low Negligible
“B”分數表示相對 ESG 表現良好，公開報告重要 ESG 數據的透明度高於平均水平。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
| 日期 | 關閉 | 更改 | 變化 (%) | 打開 | 高 | 低 |
|---|---|---|---|---|---|---|
| Dec 1, 2023 | 7.00 | 0.10 | 1.45% | 6.90 | 7.20 | 6.90 |
| Nov 30, 2023 | 6.85 | 0.00 | 0.00% | 6.85 | 7.00 | 6.75 |
| Nov 29, 2023 | 6.80 | -0.15 | -2.16% | 6.95 | 7.05 | 6.80 |
| Nov 28, 2023 | 6.95 | 0.20 | 2.96% | 6.75 | 7.00 | 6.65 |
| Nov 27, 2023 | 6.70 | -0.15 | -2.19% | 6.85 | 6.85 | 6.65 |
| Nov 24, 2023 | 6.80 | 0.05 | 0.74% | 6.75 | 6.85 | 6.75 |
| Nov 23, 2023 | 6.85 | 0.15 | 2.24% | 6.70 | 6.90 | 6.60 |
| Nov 22, 2023 | 6.70 | 0.00 | 0.00% | 6.70 | 6.70 | 6.60 |
| Nov 21, 2023 | 6.70 | -0.20 | -2.90% | 6.90 | 6.90 | 6.70 |
| Nov 20, 2023 | 6.85 | 0.15 | 2.24% | 6.70 | 6.90 | 6.65 |
| Nov 17, 2023 | 6.65 | 0.10 | 1.53% | 6.55 | 6.70 | 6.55 |
| Nov 16, 2023 | 6.60 | -0.40 | -5.71% | 7.00 | 7.00 | 6.55 |
| Nov 15, 2023 | 7.05 | 0.20 | 2.92% | 6.85 | 7.05 | 6.75 |
| Nov 14, 2023 | 6.65 | -0.05 | -0.75% | 6.70 | 6.80 | 6.60 |
| Nov 13, 2023 | 6.70 | 0.10 | 1.52% | 6.60 | 6.75 | 6.60 |
| Nov 10, 2023 | 6.65 | 0.05 | 0.76% | 6.60 | 6.70 | 6.55 |
| Nov 9, 2023 | 6.70 | -0.20 | -2.90% | 6.90 | 6.95 | 6.70 |
| Nov 8, 2023 | 6.85 | 0.10 | 1.48% | 6.75 | 7.00 | 6.75 |
| Nov 7, 2023 | 6.75 | -0.10 | -1.46% | 6.85 | 6.90 | 6.75 |
| Nov 6, 2023 | 6.95 | 0.10 | 1.46% | 6.85 | 7.25 | 6.85 |
CSPC Pharmaceutical Group Limited Events
| 时间（协调世界时） (UTC) | 国家 | 事件 |
|---|---|---|
| Wednesday, March 20, 2024 | ||
| 时间（协调世界时） (UTC) 10:59 | 国家 CN
| 事件 Full Year 2023 CSPC Pharmaceutical Group Ltd Earnings Release Full Year 2023 CSPC Pharmaceutical Group Ltd Earnings ReleaseForecast（预报） -上一页 - |
- 年度
- 每季度
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| 總收入 | 30936.9 | 27866.9 | 24942.2 | 22103.2 | 17716.5 |
| 收入 | 30936.9 | 27866.9 | 24942.2 | 22103.2 | 17716.5 |
| 收入成本，共計 | 8680.49 | 6731.78 | 6256.88 | 6192.21 | 5979.19 |
| 毛利 | 22256.4 | 21135.1 | 18685.3 | 15911 | 11737.4 |
| 總營業費用 | 23314.4 | 21034.6 | 18552.5 | 17503 | 13893.6 |
| 銷售/一般/行政費用，總計 | 11484.5 | 11457.3 | 10361.5 | 9460.59 | 6841.1 |
| 研究與開發 | 3986.52 | 3432.59 | 2889.84 | 2000.43 | 1342.1 |
| 利息費用（收入) - 淨運營 | -461.56 | -352.319 | -506.452 | -83.303 | -112.822 |
| 異常費用（收入） | 31.401 | 23.421 | -320.669 | 132.396 | 16.02 |
| Other Operating Expenses, Total | -407.021 | -258.231 | -128.57 | -199.311 | -172.01 |
| 營業收入 | 7622.55 | 6832.32 | 6389.72 | 4600.18 | 3822.96 |
| 利息收入（費用），非經營淨值 | -40.286 | 14.779 | 1.3 | 25.981 | -30.783 |
| 稅前淨收入 | 7582.26 | 6847.1 | 6391.02 | 4626.16 | 3792.18 |
| 稅後淨收入 | 6232.05 | 5688.12 | 5229.01 | 3733.35 | 3058.42 |
| 少數股東權益 | -140.66 | -82.939 | -69.355 | -19.246 | 22.383 |
| 未計算非常項目前的淨收益 | 6091.39 | 5605.19 | 5159.65 | 3714.11 | 3080.8 |
| 淨收入 | 6091.39 | 5605.19 | 5159.65 | 3714.11 | 3080.8 |
| 普通股股東可獲收益 (不含非經常性項目) | 6091.39 | 5605.19 | 5159.65 | 3714.11 | 3080.8 |
| 普通股股東可獲收益 (含非經常性項目) | 6091.39 | 5605.19 | 5159.65 | 3714.11 | 3080.8 |
| 攤薄淨收入 | 6091.39 | 5605.19 | 5159.65 | 3714.11 | 3080.8 |
| 攤薄後加權平均股 | 11918.5 | 11953.8 | 11955.5 | 11956.8 | 11984.8 |
| 扣除特別項目的每股攤薄盈利 | 0.51109 | 0.4689 | 0.43157 | 0.31063 | 0.25706 |
| Dividends per Share - Common Stock Primary Issue | 0.18547 | 0.14667 | 0.10732 | 0.0931 | 0.08231 |
| 每股正常攤薄盈利 | 0.51325 | 0.47053 | 0.40963 | 0.31956 | 0.25814 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| 總收入 | 8027.14 | 8053.27 | 7441.39 | 7885.49 | 7736.13 |
| 收入 | 8027.14 | 8053.27 | 7441.39 | 7885.49 | 7736.13 |
| 收入成本，共計 | 2308.1 | 2534.67 | 2267.28 | 2141.67 | 2208.61 |
| 毛利 | 5719.04 | 5518.6 | 5174.11 | 5743.82 | 5527.52 |
| 總營業費用 | 6118.49 | 6251.14 | 5435.82 | 5996.87 | 5768.24 |
| 銷售/一般/行政費用，總計 | 2687.35 | 2750.68 | 2522.28 | 3013 | 2890.8 |
| 研究與開發 | 1295.96 | 1007.65 | 1066.27 | 1036.17 | 982.56 |
| 利息費用（收入) - 淨運營 | -168.775 | 50.09 | -216.558 | -61.47 | -230.044 |
| 異常費用（收入） | 23.659 | -16.485 | 0.299 | 0 | |
| Other Operating Expenses, Total | -27.809 | -91.947 | -186.96 | -132.81 | -83.681 |
| 營業收入 | 1908.65 | 1802.13 | 2005.56 | 1888.63 | 1967.89 |
| 利息收入（費用），非經營淨值 | -8.059 | -21.166 | -20.369 | -11.018 | -12.351 |
| 稅前淨收入 | 1900.59 | 1780.96 | 1985.19 | 1877.61 | 1955.54 |
| 稅後淨收入 | 1588.94 | 1469.1 | 1661.1 | 1543.86 | 1592.79 |
| 少數股東權益 | -50.796 | -40.257 | -37.552 | -42.23 | -31.106 |
| 未計算非常項目前的淨收益 | 1538.14 | 1428.84 | 1623.55 | 1501.63 | 1561.69 |
| 淨收入 | 1538.14 | 1428.84 | 1623.55 | 1501.63 | 1561.69 |
| 普通股股東可獲收益 (不含非經常性項目) | 1538.14 | 1428.84 | 1623.55 | 1501.63 | 1561.69 |
| 普通股股東可獲收益 (含非經常性項目) | 1538.14 | 1428.84 | 1623.55 | 1501.63 | 1561.69 |
| 攤薄淨收入 | 1538.14 | 1428.84 | 1623.55 | 1501.63 | 1561.69 |
| 攤薄後加權平均股 | 11869.6 | 11917 | 11919.3 | 11918.7 | 11918.7 |
| 扣除特別項目的每股攤薄盈利 | 0.12959 | 0.1199 | 0.13621 | 0.12599 | 0.13103 |
| Dividends per Share - Common Stock Primary Issue | 0.12955 | 0 | 0.09715 | 0 | 0.08537 |
| 每股正常攤薄盈利 | 0.13125 | 0.1199 | 0.13506 | 0.12601 | 0.13103 |
- 年度
- 每季度
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| 流動資産總額 | 23957.2 | 20336.5 | 15921.4 | 13697 | 13803.5 |
| 現金和短期投資 | 13795.7 | 10727.1 | 8794.67 | 5956.93 | 6628.42 |
| 现金 | 8000.85 | 9283.64 | 7259.46 | 4118.24 | 4335.61 |
| 短期投資 | 5794.86 | 1443.41 | 1535.21 | 1838.69 | 2292.81 |
| 應收賬款總額，淨額 | 6836.21 | 6548.65 | 4744.78 | 4450.74 | 3629.18 |
| 應收賬款 - 貿易，淨額 | 4104.5 | 3409.28 | 2543.12 | 2399.03 | 2128.37 |
| 總庫存 | 2554.86 | 2480.37 | 1861.07 | 2535.74 | 3045.32 |
| 預付的費用 | |||||
| 其他流動資産，總計 | 770.379 | 580.425 | 520.86 | 753.545 | 500.566 |
| 總資産 | 41769.8 | 34741.6 | 30070.2 | 26318.3 | 23216.8 |
| 物業/廠房/設備，總計 - 淨額 | 10976.9 | 9563.92 | 8934.34 | 9282.38 | 6692.22 |
| 物業/廠房/設備，總計 - 總額 | 15596.2 | 13426.6 | 12177.1 | 12572.5 | 9495.94 |
| 累計折舊，總計 | -4619.31 | -3862.7 | -3242.73 | -3290.1 | -2803.72 |
| 商譽，淨額 | 234.904 | 149.983 | 149.983 | 188.964 | 140.752 |
| 無形資産，淨額 | 1908.11 | 467.854 | 508.742 | 1135.66 | 806.986 |
| 長期投資 | 3783.08 | 3356.49 | 3175.62 | 1485.71 | 898.542 |
| 其他長期資産，總計 | 909.596 | 612.871 | 622.827 | 378.223 | 874.849 |
| 流動負債總額 | 8958 | 7226.04 | 6301.84 | 6236.77 | 7247.02 |
| 應付賬款 | 1703.49 | 1481.36 | 1204.57 | 1110.88 | 1619.36 |
| 預提費用 | 728.165 | 519.256 | 385.881 | 371.337 | 445.834 |
| 應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
| 長期債務的當前部分/資本租賃 | 295.555 | 38.424 | 223.835 | 97.235 | 70.589 |
| 其他流動負債，總計 | 6230.79 | 5187 | 4487.56 | 4657.32 | 5111.24 |
| 負債總額 | 11572.2 | 8754.9 | 7737.92 | 7856.6 | 8164.58 |
| 長期債務總額 | 286.989 | 55.62 | 92.879 | 90.3 | 0 |
| 長期債務 | 28.95 | 0 | |||
| 遞延所得稅 | 611.993 | 381.484 | 320.444 | 304.427 | 237.917 |
| 少數股權 | 1444.34 | 841.559 | 768.785 | 1056.44 | 477.34 |
| 其他負債，總計 | 270.917 | 250.198 | 253.968 | 168.656 | 202.303 |
| 總權益 | 30197.5 | 25986.7 | 22332.3 | 18461.7 | 15052.3 |
| 普通股 | 10899.4 | 10899.4 | 10899.4 | 10899.4 | 10899.4 |
| 額外實收資本 | 196.574 | 46.794 | 46.794 | 46.794 | 46.794 |
| 留存收益（累計赤字） | 19163.2 | 15154.5 | 11523 | 7406 | 4055.03 |
| 其他權益，總計 | 22.047 | -28.446 | -36.246 | -26.906 | -2.403 |
| 總負債和股東權益 | 41769.8 | 34741.6 | 30070.2 | 26318.3 | 23216.8 |
| 已發行普通股總數 | 11933.2 | 11950 | 11973.8 | 11973.8 | 11973.8 |
| Unrealized Gain (Loss) | 237.134 | 53.423 | |||
| 資本租賃義務 | 258.039 | 55.62 | 92.879 | 90.3 | 0 |
| Treasury Stock - Common | -83.71 | -85.6 | -100.706 | -100.706 | 0 |
| 應收票據 - 長期 | 0 | 253.953 | 757.331 | 150.432 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| 流動資産總額 | 24381.6 | 23957.2 | 22828.5 | ||
| 現金和短期投資 | 12090.7 | 13872.9 | 13408.8 | ||
| 现金 | 10298 | 9064.22 | |||
| 短期投資 | 1625.43 | 3574.86 | 4344.54 | ||
| 應收賬款總額，淨額 | 8879.42 | 6836.21 | 6229.46 | ||
| 應收賬款 - 貿易，淨額 | 5748.08 | 4104.5 | 4009.2 | ||
| 總庫存 | 2751.95 | 2554.86 | 2624.3 | ||
| 其他流動資産，總計 | 659.499 | 693.224 | 565.944 | ||
| 總資産 | 43673.2 | 41769.8 | 38838.5 | ||
| 物業/廠房/設備，總計 - 淨額 | 11358.6 | 10976.9 | 10078.4 | ||
| 商譽，淨額 | 234.904 | 234.904 | 221.591 | ||
| 無形資産，淨額 | 2264.52 | 1908.11 | 1464.22 | ||
| 長期投資 | 4719.03 | 3783.08 | 3084.78 | ||
| 應收票據 - 長期 | 0 | 269.365 | |||
| 其他長期資産，總計 | 714.633 | 909.596 | 891.66 | ||
| 流動負債總額 | 9025.67 | 8958 | 8459.25 | ||
| 應付賬款 | 2028.8 | 1703.49 | 1675.36 | ||
| 預提費用 | 728.165 | ||||
| 應付票據/短期債務 | 0 | 0 | 0 | ||
| 長期債務的當前部分/資本租賃 | 208.477 | 295.555 | 477.111 | ||
| 其他流動負債，總計 | 6788.4 | 6230.79 | 6306.78 | ||
| 負債總額 | 11853.8 | 11572.2 | 10797.2 | ||
| 長期債務總額 | 206.785 | 286.989 | 205.449 | ||
| 資本租賃義務 | 186.885 | 258.039 | 193.659 | ||
| 遞延所得稅 | 556.576 | 611.993 | 516.071 | ||
| 少數股權 | 1692.41 | 1444.34 | 1373.84 | ||
| 其他負債，總計 | 372.317 | 270.917 | 242.602 | ||
| 總權益 | 31819.5 | 30197.5 | 28041.3 | ||
| 普通股 | 10899.4 | 10899.4 | 10899.4 | ||
| 額外實收資本 | 290.825 | 196.574 | 110.38 | ||
| 留存收益（累計赤字） | 20934.8 | 19163.2 | 17099.2 | ||
| Treasury Stock - Common | -334.67 | -83.71 | -83.71 | ||
| ESOP Debt Guarantee | |||||
| 其他權益，總計 | 29.124 | 22.047 | 15.989 | ||
| 總負債和股東權益 | 43673.2 | 41769.8 | 38838.5 | ||
| 已發行普通股總數 | 11903.2 | 11933.2 | 11933.2 | ||
| 物業/廠房/設備，總計 - 總額 | 15009.1 | 14201.4 | 13039.5 | ||
| 累計折舊，總計 | -4971.83 | -4619.31 | -4229.35 | ||
| 長期債務 | 19.9 | 28.95 | 11.79 | ||
| 現金等價物 | 10465.3 |
- 年度
- 每季度
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| 净收入/起跑线 | 7582.26 | 6847.1 | 6391.02 | 4626.16 | 3792.18 |
| 经营活动产生的现金 | 7627.06 | 4636.63 | 6739.61 | 3783.9 | 3795.29 |
| 经营活动产生的现金 | 955.461 | 838.391 | 791.967 | 673.641 | 594.006 |
| Amortization | 90.352 | 25.361 | 15.121 | 17.954 | 20.142 |
| 非现金物品 | -464.546 | -545.12 | -1077.66 | -149.795 | -131.162 |
| Cash Taxes Paid | 1334.58 | 1141.18 | 1061.02 | 866.825 | 636.074 |
| 已付现金利息 | 13.451 | 7.105 | 10.322 | 32.426 | 74.337 |
| 营运资金的变化 | -536.464 | -2529.1 | 619.16 | -1384.06 | -479.872 |
| 投资活动产生的现金 | -6795.98 | -637.326 | -2129.51 | -2457.19 | -3627.87 |
| 资本支出 | -2722.69 | -1758.45 | -1576.61 | -2122.67 | -2156.86 |
| 其他投资现金流量项目，总计 | -4073.29 | 1121.12 | -552.907 | -334.521 | -1471.01 |
| 融资活动产生的现金 | -1904.07 | -2196.61 | -1470.98 | -1545.54 | -151.387 |
| 融资现金流项目 | 342.338 | -20.164 | -19.961 | -1590.8 | 1497.52 |
| Total Cash Dividends Paid | -2096.96 | -1690.76 | -1527.69 | -965.385 | -782.875 |
| 股票的发行（报废），净额 | -14.211 | -263.512 | 0 | 1122.79 | -83.433 |
| 债务的发行（退还），净额 | -135.239 | -222.167 | 76.679 | -112.153 | -782.598 |
| 外汇效应 | 14.136 | -2.444 | 2.101 | 1.455 | 3.014 |
| 现金净变化 | -1058.86 | 1800.25 | 3141.22 | -217.377 | 19.049 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Cash From Operating Activities | 7627.06 | 4257.13 | |||
| Cash Interest Paid | 13.451 | 9.722 | |||
| Changes in Working Capital | 7627.06 | 4257.13 | |||
| Cash From Investing Activities | -6795.98 | -5703.2 | |||
| Capital Expenditures | -2722.69 | -970.212 | |||
| Other Investing Cash Flow Items, Total | -4073.29 | -4732.98 | |||
| Cash From Financing Activities | -1904.07 | -758.222 | |||
| Financing Cash Flow Items | 342.338 | 1.426 | |||
| Total Cash Dividends Paid | -2096.96 | -1019.16 | |||
| Issuance (Retirement) of Debt, Net | -135.239 | 273.728 | |||
| Foreign Exchange Effects | 14.136 | 9.592 | |||
| Net Change in Cash | -1058.86 | -2194.69 | |||
| Cash Taxes Paid | |||||
| Issuance (Retirement) of Stock, Net | -14.211 | -14.211 |
| 投資者名稱 | 投資者類型 | 流通股百分比 | 持有股份 | 股份變動 | 持有日期 | 換手率 |
|---|---|---|---|---|---|---|
| Cai (Dong Chen) | Individual Investor | 13.2783 | 1580541200 | 0 | 2023-07-14 | LOW |
| Massive Giant Group Ltd. | Corporation | 10.2395 | 1218834470 | 0 | 2023-07-14 | LOW |
| Common Success International Ltd. | Corporation | 6.1227 | 728796313 | 0 | 2022-12-31 | |
| UBS Asset Management (Hong Kong) Limited | Investment Advisor | 4.8723 | 579963670 | 4154000 | 2023-10-19 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.7965 | 332869110 | -8482000 | 2023-10-13 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.4112 | 287010955 | 720000 | 2023-09-30 | LOW |
| First Sentier Investors (Hong Kong) Limited | Investment Advisor | 1.9542 | 232607441 | 0 | 2023-07-31 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.1239 | 133781812 | -11247505 | 2022-12-31 | LOW |
| Bosera Asset Management Co., Ltd. | Investment Advisor | 0.9117 | 108516000 | 38734000 | 2023-06-30 | MED |
| State Street Global Advisors Asia Ltd. | Investment Advisor/Hedge Fund | 0.8414 | 100159631 | 2941263 | 2023-09-30 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 0.8024 | 95512893 | -1162000 | 2023-10-13 | LOW |
| BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.791 | 94153373 | -1338000 | 2023-09-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.6897 | 82097360 | 424000 | 2023-09-30 | LOW |
| Caisse de Depot et Placement du Quebec | Pension Fund | 0.5929 | 70568837 | -24043283 | 2022-12-31 | LOW |
| Hang Seng Investment Management Ltd. | Investment Advisor | 0.5768 | 68663594 | 6425512 | 2023-09-30 | LOW |
| Nuveen LLC | Pension Fund | 0.5683 | 67642450 | 3210248 | 2023-09-30 | LOW |
| Harvest Fund Management Co., Ltd. | Investment Advisor | 0.5669 | 67478040 | 14808000 | 2023-06-30 | MED |
| California State Teachers Retirement System | Pension Fund | 0.5135 | 61119044 | 4562352 | 2022-06-30 | LOW |
| Zhong Ou Asset Management Co., Ltd. | Investment Advisor | 0.4479 | 53310000 | -14704000 | 2023-06-30 | MED |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.4204 | 50046943 | -19426968 | 2023-01-31 | LOW |
差價合約交易計算器
如果您在特定日期（選取一個日期）開立差價合約交易並在不同日期（選取一個日期）關閉交易，計算您的假設盈虧。
交易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模（槓桿 x 投資）：
打開
關閉
做空 做多
CSPC Pharmaceutical Company profile
石药集团有限公司，英文名称：CSPC Pharmaceutical Group Limited，是一家投资控股公司，在中国及全球其他地区从事医药产品的生产和销售业务。石药集团有限公司成立于1997年，总部位于石家庄，前身为中国医药集团有限公司，于2013年3月更名为中海集运药业集团有限公司。
石药集团的业务范围包括成品药，抗生素，维生素C和咖啡因等。销售产品有NBP恩必普（丁苯酞软胶囊及注射液）；欧来宁胶囊和注射剂（用于治疗由血管性痴呆，老年性痴呆和脑外伤引起的轻度至中度记忆和精神损害）；玄宁降压药；多美素（用于淋巴瘤，多发性骨髓瘤，卵巢癌和乳腺癌等恶性肿瘤）；津优力（用于预防化疗引起的白细胞减少和感染）; 艾利能（用于神经胶质瘤和脑转移，并辅助治疗恶性胸膜和腹腔积液）；诺利宁（用于治疗慢性粒细胞和急性淋巴细胞白血病）。
此外，石药集团还生产销售仿制药，包括欧意消炎药、治疗骨质疏松症的固邦、治疗感染的维宏、维生素C含片果维康；中药；抗生素，包括阿莫西林和氨苄青霉素胶囊，头孢曲松钠和头孢唑啉钠注射剂，以及美罗培南注射剂。此外，该公司还生产抗生素，维生素C和咖啡因原料药；研究和开发各种产品，主要集中在心脑血管疾病，代谢疾病，肿瘤学，精神病学和神经病学的治疗领域。不仅如此，石药集团还从事药品研发，原料药采购、仓储、分销，污水和药物副产品处理。
| Industry: | Pharmaceuticals (NEC) |
黃河大道路226號
SHIJIAZHUANG
HEBEI 050035
CN
收入報表
- Annual
- Quarterly
人們也觀看
还在找一位您可以信任的经纪商吗？
加入成为全球570,000万多名交易者的一份子，选择利用Capital.com进行交易吧。